Los Angeles Capital Management LLC Sells 35,733 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Los Angeles Capital Management LLC lessened its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 15.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 194,737 shares of the company’s stock after selling 35,733 shares during the period. Los Angeles Capital Management LLC’s holdings in Amneal Pharmaceuticals were worth $2,454,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Comerica Bank increased its position in Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares in the last quarter. Spire Wealth Management boosted its stake in Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares during the last quarter. Focus Partners Wealth purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at $42,000. Advisory Services Network LLC purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at $50,000. Finally, Strs Ohio purchased a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $52,000. Institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

AMRX has been the topic of several recent analyst reports. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Barclays increased their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Truist Financial increased their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. UBS Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 target price on the stock. Finally, Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.80.

Insider Activity

In other news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 17.30% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $14.69 on Wednesday. The company has a market cap of $4.69 billion, a P/E ratio of 38.66 and a beta of 1.30. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.53 and a 1 year high of $15.42. The stock’s fifty day moving average price is $12.82 and its 200-day moving average price is $13.02.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The firm had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. As a group, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.